Insights & Resources | Pfizer CentreOne

What Makes Us Altogether Different

For over 40 years, we've been listening, solving, and guiding our partners' drug projects to success. But what makes us an altogether different kind of CDMO to work with? Find out here.

Pfizer CentreOne Wins Medicine Maker CDMO of the Year Award

The first annual CDMO of the Year Award by the Medicine Maker has wrapped up for 2022 and we’re pleased to announce that Pfizer CentreOne has been crowned the winner!

Glass Vial vs PFS Processing: What’s the Difference?

Prefilled syringes (PFS) have become an increasingly attractive choice for medical professionals, especially in recent years in this article we’ll be discussing the differences between glass vials and PFS that manufacturers must account for in their switch to PFS devices.

Transitioning from a Vial to PFS: What are the Benefits?

The development of parenteral drugs has increased significantly, with the market set to reach $1.2 billion USD by 2028¹. Combined with the latest advancements in medical technology, an increasing number of parenteral drug developers are turning from traditional glass vials to prefilled syringes (PFS).

Making the Move: Migrating a Drug Product from Vial to Prefilled Syringe

In this article we're continuing our conversation on migrating parenteral drug products from traditional glass vials to PFS devices, we’ll focus on the technical aspects of this change, discussing the analytical requirements and screening requirements that must be followed when migrating a drug product from a vial to PFS.

CMO Leadership Awards 2022: Pfizer CentreOne Wins for Sixth Consecutive Year

Pfizer CentreOne wins CMO leadership awards for sixth consecutive year, learn what it means to the in this interview with Andrew Moore

Balancing Pressing Priorities

In the latest roundtable discussion with BioPharm International, our contract manufacturing lead Tom Wilson spoke alongside other industry leaders about these supply chain challenges and how we were able to change our business processes and develop best practices to ensure effective remote partnerships.

Considerations for Migrating a Drug Product Presentation from Vial to Pre-Filled Syringe

This whitepaper outlines the benefits of PFS transfer, the differences between glass and PFS devices, and the key engineering processes required to successfully carry out this process.

Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms

In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.

Placing Drug Strategies on a Solid Foundation for Success

Our whitepaper explores current market dynamics and the latest drug development trends driving these strategic outsourcing decisions.

Migrating A Drug Product Presentation From Vial To Prefilled Syringe - On Drug Delivery

This article explores some of the leading engineering activities that are necessary for successful PFS transfers and the benefits they offer.

Understanding the Challenges of Highly Potent Actives - International Pharmaceutical Industry

From managing health and safety risks to effective potency classifications, there are many challenges pharmaceutical companies face when using highly potent active pharmaceutical ingredients (HPAPIs) for the first time. This article explores these challenges in-depth and how they can be overcome.